UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000012551 |
|---|---|
| Receipt number | R000014685 |
| Scientific Title | A Phase II, Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Trastuzumab (Herceptin) in Patients with Her2 Overexpression/Amplification/Mutation-Positive, Pretreated, Non-Small Cell Lung Cancer (HER2-CLHERC-B/HOT1303-B) |
| Date of disclosure of the study information | 2013/12/11 |
| Last modified on | 2021/08/25 14:44:58 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/12/11 17:37:57 | ||
| 2 | Update | 2013/12/11 20:14:54 | Acronym |
|
| 3 | Update | 2013/12/11 20:15:56 | Condition |
|
| 4 | Update | 2013/12/11 20:36:18 | Key inclusion criteria Key inclusion criteria |
|
| 5 | Update | 2013/12/11 20:55:27 | Date of disclosure of the study information |
|
| 6 | Update | 2014/03/21 00:43:39 | Recruitment status |
|
| 7 | Update | 2014/03/21 00:57:44 | Key inclusion criteria Key inclusion criteria |
|
| 8 | Update | 2014/03/21 01:01:00 | Key inclusion criteria Key inclusion criteria |
|
| 9 | Update | 2015/12/01 01:07:41 | Key inclusion criteria Key inclusion criteria |
|
| 10 | Update | 2017/05/11 23:20:11 | Recruitment status |
|
| 11 | Update | 2021/08/25 14:44:58 | Recruitment status Date of IRB Last follow-up date Date of closure to data entry Date trial data considered complete |
